Back to Search
Start Over
A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)
- Source :
- Journal of Clinical Oncology. 26:14603-14603
- Publication Year :
- 2008
- Publisher :
- American Society of Clinical Oncology (ASCO), 2008.
-
Abstract
- 14603 Background: Emergence of targeted therapy for MRCC has been a turning point in improving outcomes. Evaluation of a tyrosine kinase inhibitor (TKI) plus an mTOR inhibitor to increase the magni...
- Subjects :
- Oncology
Sorafenib
Cancer Research
medicine.medical_specialty
Everolimus
medicine.drug_class
business.industry
medicine.medical_treatment
urologic and male genital diseases
Discovery and development of mTOR inhibitors
Tyrosine-kinase inhibitor
respiratory tract diseases
Phase i study
Targeted therapy
Regimen
Internal medicine
medicine
Metastatic renal cell cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........b765a63e6d6b8f540ce7817a70342019